Pilot study of intravenous administration of the acid-treated Salmonella minnesota R595 (Re) in cancer patients.
The clinical toxicity of acetic acid-treated "Salmonella minnesota" R595 (Re) organisms was evaluated in 24 cancer patients. Bacteria were injected i.v. four times at increasing doses for a total of 6.5 micrograms. This therapeutic regimen was free of major side effects (one patient had fever higher than 38 degrees C and 10 patients complained of pruritus). Furthermore, this bacterial preparation which possesses a more exposed lipid A on its surface, exhibited immunomodulating capacities in that it normalized the inverted T helper/T suppressor ratio and enhanced natural killer activity in tumor patients. The mechanisms of the lower toxicity and immunomodulating activities of these bacteria compared to other lipid A preparations are discussed.
D000085:Acetates; D019342:Acetic Acid; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007694:Killer Cells, Natural / Q000276:immunology; D007958:Leukocyte Count; D008050:Lipid A / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012475:Salmonella / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer; D050378:T-Lymphocytes, Regulatory
D000085:Acetates; D008050:Lipid A; D019342:Acetic Acid